Many participants played a role in discovering the composition and sequence of the Abeta amyloid of Alzheimer's disease. This sequence enabled the cloning of the amyloid precursor protein (APP), which elucidated its proteolytic origin from the membrane of neurons. The proteolytic enzymes which process APP and the Abeta fragment itself are now the prime validated drug targets for therapeutic intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/jad-2006-9s318 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!